Comparative Pharmacology
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus NUPLAZID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus NUPLAZID.
LURASIDONE HYDROCHLORIDE vs NUPLAZID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lurasidone is an atypical antipsychotic that acts as a full antagonist at D2 and 5-HT2A receptors, with high affinity for 5-HT7 and 5-HT1A receptors, moderate affinity for alpha2C and alpha2A adrenergic receptors, and no appreciable affinity for H1, M1, or alpha1 receptors.
Selective serotonin 5-HT2A receptor inverse agonist and antagonist; also has moderate affinity for 5-HT2C and 5-HT1A receptors.
40 mg orally once daily initially, titrated to 80 mg once daily; maximum 80 mg per day.
34 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 14–24 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 50 hours (range 40-70 hours), allowing once-daily dosing.
Approximately 80% of total radioactivity recovered in feces (67% as metabolites, 9% as unchanged drug) and 19% in urine (mostly metabolites); less than 1% excreted as unchanged parent in urine.
Fecal (approximately 60%) as unchanged drug and metabolites; renal (approximately 13%) as unchanged drug and metabolites.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic